U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250633) titled 'Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants' on Nov. 18.
Brief Summary: The objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of one dose of vorasidenib in participants with severe impaired hepatic function compared to participants with normal hepatic function. The study includes a screening phase, a treatment period, and a follow-up period. During the first part of the treatment period, from Day 1 through Day 4, participants will remain in-house in the clinical research unit. In the second part of the treatment period, from Day 5 through Da...